期刊
PEDIATRIC HEMATOLOGY AND ONCOLOGY
卷 32, 期 8, 页码 557-567出版社
TAYLOR & FRANCIS INC
DOI: 10.3109/08880018.2015.1088905
关键词
adverse events; children; therapeutic drug monitoring; treatment response; voriconazole
Voriconazole is an antifungal drug used to treat fungal infections. This was a retrospective study of 61 children with hemato-oncologic diseases or solid organ transplantation who were administered voriconazole for invasive fungal infections. Of the 61 patients, 31 (50.8%) were in the therapeutic drug monitoring (TDM) group, and 30 (49.2%) were in the non-TDM group. At 12 weeks, treatment failure rate in the non-TDM group was higher than the TDM group (78.6% versus 40.0%, p = 0.038). Drug discontinuation due to adverse events was less frequent in the TDM group than the non-TDM group (26.0% versus 92.3%, p = 0.001). Children required higher dosages to maintain drug levels within the targeted therapeutic range: an average of 8.3mg/kg/dose in patients <12years old and 6.9mg/kg/dose for those >= 12years old. Treatment failure rates were higher in patients whose voriconazole levels remained below 1.0mg/L for more than 50% of their treatment duration than those above 1.0mg/L (71.4% vs. 9.1% after 12 weeks, p = 0.013). Serial monitoring of voriconazole levels in children is important for improving treatment response and preventing unnecessary drug discontinuation. Higher dosages are needed in children to reach therapeutic range.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据